ReviewCurrent topics in medicinal chemistry2026
Microfluidics-based Polymeric Micro/Nanocarriers for Drug Delivery in Liver Cancer Treatment: Recent Advances, Outlooks, and Progress.
Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microfluidics-based polymers are transforming drug delivery systems for liver cancer treatment as they enable precise synthesis of nano- and microparticles suitable for targeted therapy. The manufacture of programmable nanoparticles and tunable sizes is made possible by microfluidic platforms, which are essential for improving the effectiveness of medication administration. A wide range of therapeutic chemicals, including hydrophobic medications like doxorubicin, can be encapsulated in these systems to target liver cancers while reducing systemic toxicity effectively. It has also been demonstrated that combining natural hydrogels and droplet microfluidics can create multicellular tumor spheroids that resemble the tumor microenvironment more closely. This methodology improves screening and drug efficacy research and offers a strong foundation for assessing treatment outcomes. This research also explores novel uses of microfluidic technologies to develop intelligent drug delivery devices that respond to particular stimuli and release medication at the tumor site. It also investigated how artificial cell assemblies made with microfluidics can open new possibilities for individualized cancer treatment. To sum up, microfluidic-based polymers offer advanced tools for developing tailored and efficient drug delivery systems that can enhance patient outcomes, and represent a significant advancement in the treatment of liver cancer. The review paper discusses challenges in liver cancer treatment, including high drug clearance rates, low concentrations, and multidrug resistance. It suggests microfluidic technology can improve drug delivery systems by creating controlled particles and responding to tumor conditions. This could revolutionize liver cancer therapies, enabling better drug testing and treatment prediction, as well as designing tailored therapies.
Indexed as
Identifiers
40736001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.